INGENUITY CREATES MILESTONES

OF INTELLIGENT MANUFACTURING

MicroPort® MedBot® Announces 2022 Interim Results
2022-09-01 GMT+8 PM 08:30

Shanghai, China - Shanghai MicroPort MedBot (Group) Co., Ltd. (stock code: 02252.HK, hereinafter referred to as "MicroPort® MedBot®"), a subsidiary of MicroPort Scientific Corporation (stock code: 00853.HK, hereinafter referred to as "MicroPort® Group") announced the results of the company and its subsidiaries (hereinafter referred to as “the Company”) for the six months as of June 30, 2022 (hereinafter referred to as the “Reporting Period”) on August 26, 2022.

 

In the first half of 2022, the company adheres to the focus on the construction of a surgical robot technology innovation platform and an industrialized operation system, continues to strengthen internal management and external market expansion, accelerates the deployment of multi-domain surgical robots, continues to build clinical application-oriented training and education platform, deepens the inclusive industry-university-research cooperation, strengthens the industrialization of the whole life cycle and the intelligent operation and maintenance system, builds the global commercialization capability of the products, and continues to make steady progress in the fields of product research and development, clinical trials, and commercialization of the surgical robots.

 

During the reporting period, MicroPort® MedBot® obtained the listing registration certificate issued by the drug regulatory department and the US FDA certification for a number of core products, and completed relevant clinical trials; through the integration with 5G technology, completed the world's longest-distance ultra-remote 5G robotic surgery so far; made the milestone progress in the commercialization process, and won the bid for the procurement of the first Toumai® Hospital; established cooperation with nearly 100 hospitals, and successfully carried out more than 1,000 cases of clinical verification and doctor training operations.

 

MicroPort® MedBot®, currently as the only surgical robot company in the world that covers the five "Gold Races" of endoscope, orthopedics, vascular intervention, natural orifice and percutaneous puncture, has more than ten products in the stage of rapid industrialization project promotion, and has made important progress during the reporting period.

 

In January 2022, the Toumai® Endoscopic Surgery Robot (“Toumai®”) obtained the listing registration certificate issued by the Food and Drug Administration, becoming the first and only four-armed endoscopic surgery robot developed by a Chinese company and approved for marketing so far. Meanwhile, Toumai® completed the registered clinical trial in April 2022. Toumai® has become the second in the world and the first in China endoscopic surgery robot that fully covers the important and complex surgical procedures for clinical applications in the fields of thorax, abdominal cavity and pelvic cavity, representing the comprehensive expansion of domestic endoscopic surgery robots in the field of clinical applications.

 

In March 2022, the robot-assisted bronchoscopic navigation system independently developed by the company successfully completed the first robot-assisted transbronchoscopic lung nodule biopsy during the reporting period, which filled the gap in China and was expected to solve the clinical dilemma of early diagnosis and treatment of cancer.

 

In April 2022, Honghu Orthopedic Surgical Robot ("Honghu") obtained the listing registration certificate issued by the Food and Drug Administration, opening a new chapter for the company's comprehensive layout in the orthopedic field. Honghu is also the first and only orthopedic surgical robot equipped with the robotic arm independently developed by a Chinese company with its own intellectual property rights, and approved for listing. Honghu (U.S. registered name SkyWalkerTM) obtained the FDA's 510(k) certification in July 2022, becoming the first and only Chinese surgical robot certified by the FDA so far, which marks that China's surgical robot industry innovation has entered the international advanced ranks.

 

In April 2022, the iSR'obot® Mona Lisa Robotic Prostate Puncture Biopsy System (hereinafter referred to as the “Mona Lisa”) of Shanghai Jiehang, a joint venture company established in China by the Company and Singapore Biobot Surgical Pte. Ltd., completed the enrollment in registered clinical trials in China during the reporting period, becoming the first prostate puncture robot to complete the enrollment in registered clinical trials in the field of urology and taking a key step in accurate diagnosis and treatment of prostate cancer. So far, Shanghai Jiehang has submitted a registration application for Mona Lisa to NMPA.

 

In May 2022, the R-ONE® Vascular Interventional Surgery Robot (hereinafter referred to as "R-ONE®") introduced by Shanghai Cathbot®, a joint venture company established in China by the Company and French Robocath, has completed the enrollment in all registered clinical trials in China, which is the first cardiovascular interventional robot system in China to complete the enrollment in multi-center registered clinical trials, promoting the vascular interventional surgery to become more accurate and intelligent.

 

MicroPort® MedBot® has always attached great importance to technological innovation, and has continuously increased the research and development of cutting-edge technologies, especially investing a lot of resources in 5G remote surgery. It is hoped that through 5G remote surgery, the ability of hospitals in remote areas to carry out complex surgery will be improved, so that patients can receive remote surgical treatment from top experts “without leaving their hometowns”, and there is no need to seek medical treatment in other places in this scenario.

 

During the reporting period, Toumai® successfully completed the world’s longest distance 5G remote robotic surgery so far that spanned nearly 5,000 kilometers across China through a 5G connection between the People’s Hospital of Kizilsu Kirghiz Autonomous Prefecture, Xinjiang Uygur Autonomous Region and Jiangsu Province Hospital, demonstrating China’s breakthrough and leadership in 5G ultra-long-distance surgery. In the future, the company will continue to focus on the research and development of 5G remote surgery technology to facilitate the effective availability and rational distribution of high-quality medical resources, thus bringing the possibility of performing difficult and complex surgeries in more remote and underdeveloped areas.

 

In July 2022, the 5G remote precision minimally invasive surgery training center jointly built by the company and the PLA General Hospital was officially established, which is the first 5G remote precision minimally invasive surgery training center in China and even in the world. The company believes that the establishment of the 5G remote training center is of great significance for promoting the standardized training and promotion of domestic robotic surgery technology and improving the diagnosis and treatment capabilities of primary hospitals.

 

MicroPort® MedBot® has established a full-process commercial promotion system including academic promotion, clinical support, patient education and even after-sales service, providing hospitals with a full range of services such as doctor training, surgical follow-up, repair and maintenance, and equipment adjustment. During the reporting period, the company achieved a milestone in the commercialization process and won the bid for the procurement of the first Toumai® Hospital. The DFVision® 3D Electronic Endoscope has been installed in nearly 40 hospitals for admission promotion, breaking the long-term occupation of China's 3D Electronic Endoscope Market by international endoscope brands.

 

At the same time, the company has achieved leap-forward expansion in clinical validation and physician training. The company has established cooperation with nearly 100 hospitals with Toumai® and Honghu, and successfully carried out more than 1,000 cases of clinical verification and doctor training operations. The large-scale verification in the real environment fully proves the safety and effectiveness of the company's core products. During the reporting period, the company also carried out the Honghu Yunnan trip, covering 14 hospitals in 9 prefectures and performing domestic robot-assisted knee replacement surgeries on 50 local patients, including several first cases in the region, which was recognized by local hospitals and patients.

 

Under the targeted and characteristic marketing strategy and training system construction plan, the company has deployed nearly 30 clinical application and training centers across the country, and has carried out a series of clinical training and technical guidance activities for surgical robots, in order to lay a solid foundation for the subsequent further improvement of product recognition and large-scale commercialization.

 

While deeply cultivating the Chinese surgical robot market, the company continues to promote the process of globalization. In response to the U.S. FDA certification for Honghu, the company has also launched the commercialization in the U.S. market. Currently, the first training center has been set up in the U.S. to carry out doctor training. The continuous construction of overseas R&D centers in the United States has absorbed innovative ideas and resources in the field of international surgical robots, thereby accelerating the process of globalization development.

 

Dr. He Chao, Executive Director and President of MicroPort® MedBot®, said: "In the first half of 2022, despite the repeated challenges of the epidemic, with the unremitting efforts of all MicroPort® MedBot® staff, the company's key performance has continued to improve steadily. Among them, core products have been approved for the market in succession, R&D projects have entered or completed clinical trials one after another, and doctor training and clinical verification have been continuously deepened, so that the company's leading position in the industry can be further consolidated. In the future, the company will steadily strengthen R&D and innovation to improve the product line of intelligent surgical solutions, accelerate the commercialization of core products to optimize the medical robot innovation platform with strong potential, and make continuous efforts for the growth of the domestic surgical robot industry and the outbreak of clinical applications."

 

 

For more information,
please click here.